SCHEMBL30049383

SCHEMBL30049383

O=C1OCCN1c1ccc(S(=O)(=O)N2CCC3(CCN(Cc4ccccc4)CC3)CC2)cn1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 8/20 0.53
▸ TSHR P16473 6/20 0.53
▸ USP2 O75604 5/20 0.53
▸ CYP3A4 P08684 5/20 0.53
▸ CYP2C9 P11712 2/20 0.53
▸ TP53 P04637 1/20 0.53
▸ ALDH1A1 P00352 6/20 0.48
▸ MAPK1 P28482 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ HIF1A Q16665 1/20 0.48
▸ LMNA P02545 2/20 0.44
▸ CYP1A2 P05177 2/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ GAA P10253 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27162693 1.00 CYP2D6 (0.53) CYP2D6TSHRUSP2CYP3A4CYP2C9
SCHEMBL30050935 0.94 CYP2D6 (0.48) CYP2D6TSHRUSP2CYP3A4CYP2C9
SCHEMBL27161433 0.94 CYP2D6 (0.48) CYP2D6TSHRUSP2CYP3A4CYP2C9
SCHEMBL27162473 0.90 CYP3A4 (0.56) CYP2D6TSHRUSP2CYP3A4CYP2C9
SCHEMBL30049623 0.90 CYP3A4 (0.56) CYP2D6TSHRUSP2CYP3A4CYP2C9
SCHEMBL27162156 0.90 CYP2D6 (0.62) CYP2D6TSHRUSP2CYP3A4CYP2C9
SCHEMBL30050997 0.90 CYP2D6 (0.62) CYP2D6TSHRUSP2CYP3A4CYP2C9
SCHEMBL30050034 0.87 SMN1; SMN2 (0.43) CYP2D6TSHRUSP2CYP3A4CYP2C9
SCHEMBL27162198 0.87 SMN1; SMN2 (0.43) CYP2D6TSHRUSP2CYP3A4CYP2C9
SCHEMBL30049333 0.84 ALDH1A1 (0.42) CYP2D6TSHRUSP2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 CYP2D6 514/4885TSHR 540/4885USP2 2065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback